CEO says AstraZeneca likely to run new global trial of COVID-19 vaccine - Bloomberg News

(Reuters) - AstraZeneca is likely to run an additional global trial to assess the efficacy of its COVID-19 vaccine, its chief executive Pascal Soriot was quoted as saying on Thursday after questions over the results from its late-stage study. Instead of adding the trial arm to an ongoing U.S. process, a new study would be run to evaluate a lower dosage that performed better than a full amount in AstraZeneca's studies, Soriot was quoted as saying in a Bloomberg News report

Reuters November 27, 2020 00:06:40 IST
CEO says AstraZeneca likely to run new global trial of COVID-19 vaccine - Bloomberg News

COVID-19 vaccine - Bloomberg News" src="https://images.firstpost.com/wp-content/uploads/reuters/11-2020/27/2020-11-26T170937Z_3_LYNXMPEGAP13C_RTROPTP_2_HEALTH-CORONAVIRUS-ASTRAZENECA-DATA.jpg" alt="CEO says AstraZeneca likely to run new global trial of COVID19 vaccine Bloomberg News" width="300" height="225" />

(Reuters) - AstraZeneca is likely to run an additional global trial to assess the efficacy of its COVID-19 vaccine, its chief executive Pascal Soriot was quoted as saying on Thursday after questions over the results from its late-stage study.

Instead of adding the trial arm to an ongoing U.S. process, a new study would be run to evaluate a lower dosage that performed better than a full amount in AstraZeneca's studies, Soriot was quoted as saying in a Bloomberg News report.

"Now that we've found what looks like a better efficacy we have to validate this, so we need to do an additional study," Soriot was quoted as saying.

Soriot said it would probably be another "international study, but this one could be faster because we know the efficacy is high so we need a smaller number of patients".

The news comes as AstraZeneca faces questions about its success rate that some experts say could hinder its chances of getting speedy U.S. and EU regulatory approval.

Several scientists have raised doubts about the robustness of results released on Monday showing the experimental vaccine was 90% effective in a sub-group of trial participants who, by error initially, received a half dose followed by a full dose.

Soriot said he did not expect the additional trial to delay UK and European regulatory approvals.

Clearance from the U.S. Food and Drug Administration (FDA) may take longer though because the agency is unlikely to approve the vaccine based on studies carried out elsewhere, especially given the questions over the results, he said.

Authorisation in some countries is still expected before the end of the year, he added.

AstraZeneca research chief Mene Pangalos told Reuters on Monday that researchers had stumbled upon the half-dose regime by accident, saying a sub-group of the trial was given a smaller initial dose by mistake.

Earlier he had said that the firm would start discussions with the FDA to change the design of its experimental COVID-19 vaccine trial to add the more-effective dosage regime.

(Writing by Josephine Mason; Editing by Jan Harvey, Alexander Smith and Pravin Char)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

Target holiday sales jump 17% as shoppers splurge online
Business

Target holiday sales jump 17% as shoppers splurge online

By Uday Sampath Kumar (Reuters) - Target Corp reported a 17.2% rise in comparable sales for the holiday season on Wednesday as its online sales more than doubled, thanks to faster deliveries and higher demand for home goods, electronics and beauty products.

S&P 500, Nasdaq tick higher on Intel boost
Business

S&P 500, Nasdaq tick higher on Intel boost

By Medha Singh and Devik Jain (Reuters) - The S&P 500 and the Nasdaq rose in choppy trading on Wednesday as Intel shares jumped thanks to a change in management while broader sentiment was muted after a recent run to record highs. Intel said it would replace Chief Executive Officer Bob Swan with VMware Inc CEO Pat Gelsinger next month

Bolivia signs contract with India's Serum Institute for 5 million AstraZeneca vaccine doses
Business

Bolivia signs contract with India's Serum Institute for 5 million AstraZeneca vaccine doses

By Danny Ramos LA PAZ (Reuters) - The Bolivian government said on Wednesday it had signed a contract with India's Serum Institute for the supply of 5 million doses of AstraZeneca's COVID-19 vaccine. President Luis Arce said that combined with a recent deal to buy 5.2 million Sputnik V vaccine doses from Russia, Bolivia now expected to be able to inoculate all of its vaccinable population. Both vaccines require two doses to be given, meaning they would be used to inoculate a total of 5.1 million people from Bolivia's 11.51 million-strong population.